CTRI/2022/10/046324已完成未知
A Proof-of-Concept, Placebo-Controlled, Safety, and Efficacy Study of Plant Based Biotin in Healthy Adult Human Subjects with thin, dry, and brittle hair.
Zywie Ventures Private Limited0 个研究点目标入组 51 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 51
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)Age: 30 to 55 years (both inclusive) at the time of consent.
- •2)Sex: Healthy males and non-pregnant/non-lactating females.
- •3)Females of childbearing potential must have a self-reported negative pregnancy test.
- •4)Subject are generally in good health.
- •5)Subject with self-proclaimed nonpathological thin, dry and brittle hair.
- •6)Subject with normal Fitzpatrick skin type III to VI (Human skin colour determination scale).
- •7)Subject has a score of at least â??mild skin agingâ?? based on PGA at screening visit.
- •8)Subject with Glogau Skin Age II or III as assessed by the Dermatologist/ Dermatologist Trained Evaluator.
- •9)Subject is willing to forgo cosmetic procedures 3 months prior to and for the duration of the study.
- •10)Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.
- •11)Subject is able to follow their normal skin care routines and to refrain from introducing any new skin care products during the study.
- •12)Subject is able to forgo changes in baseline medications and nutritional supplements during the study period.
- •13)If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
- •14)If currently using hormonal contraception, has been using this form of contraception for at least 6 months and agrees to continue using the same contraception for the duration of the study.
- •15)Subjects are willing not to introduce any new soaps, cleansers, laundry detergents, lotions, creams, shampoos etc. for the duration of the study.
- •16)Subjects are willing to give written informed consent and are willing to follow the study procedure.
- •17)Subjects who have used other marketed products for hair thinning in the past.
- •18)Subjects who commit not to use medicated/ prescription shampoos/hair care products (containing Minoxidil / Anti-thinning agents) or any other hair growth, treatment for thin hair, or hair products other than the test product for the entire duration of the study.
- •19)Willing to use test product throughout the study period
排除标准
- •Subjects must not be enrolled in the study if they meet any one of the following criteria:
- •1)Subjects with a history of hair thinning/hair fall due to any clinically significant problems/s like anaemia, thyroid problems, etc.
- •2)Subject has a history of allergy or sensitivity to the test treatment ingredients like sesbania agati and others etc.
- •3)Subject has a history of any dermatological condition of the scalp other than hair loss and/or dandruff or active dermatological condition that might interfere with the clinical assessments (e.g. tattoos, eczema, psoriasis, acne, etc.).
- •4)Subject has used any systemic therapy with chronic antibiotic therapy, retinoids, and/or oral steroids during the 4 weeks prior to the start or anticipates having to use at any point during the study.
- •5)Subject has applied any topical retinoids within 2 weeks of the screening visit or anticipates having to use at any point during the study.
- •6)Subject is not willing to avoid unprotected sun or other UV radiation exposure during the study period.
- •7)Subject is currently pregnant/breastfeeding.
- •8)Subject has a history of prior use of hair growth treatment within 3 months.
- •9)Subject has a history of any prior hair growth procedures (e.g., hair transplant or laser).
- •10)Subject has a history of alcohol or drug addiction.
- •11)Subjects who have plans of shaving scalp hair during the study.
- •12)Subject has a past or present condition of irritated or visibly inflamed scalp or severe scalp disease.
- •13)Subject who is currently participating in or planning on starting weight loss program that may result in a significant change in overall body weight.
- •14)Any other condition which could warrant exclusion from the study, as per the dermatologistâ??s/investigatorâ??s discretion.
- •15)Pregnant or breastfeeding or planning to become pregnant during the study period.
- •16)History of chronic illness which may influence the cutaneous state.
- •17)Subjects participating in other similar cosmetics, devices or therapeutic trials or hair/scalp/skin care products within the last four weeks
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe Restless Legs Syndrome. - NDEUCTR2005-005372-32-ITGLAXO SMITHKLINE400
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of two doses of ketoprofen (as lysinate) lozenges (6.25mg and 12.5mg ) in patients with sore throat” - KRYSTAupper respiratory illness : sore throatMedDRA version: 9.1Level: LLTClassification code 10041367Term: Sore throatEUCTR2008-008265-36-FRSANOFI-AVENTIS GROUPE835
进行中（未招募）
1 期
The effect of Tiotropium+olodaterol fixed dose combination on exercise endurance time during constant work load cycle test in patients with COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-004253-11-GBBoehringer Ingelheim Limited544
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of two doses of ketoprofen lysinate lozenges (6.25mg and 12.5mg ) in patients with sore throat” - KRYSTAEUCTR2008-008265-36-FISANOFI-AVENTIS GROUPE835
进行中（未招募）
不适用
Efficacy and safety of 2 doses of Tiotropium Respimat compared to placebo in adolescents with severe persistent asthmapatients of either sex, 12 to 17 years old, with a diagnosis of severe persistent asthmaMedDRA version: 14.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-021778-13-DEBoehringer Ingelheim Pharma GmbH & Co. KG375